US Patent 10513530 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
Patent 10513530 was granted and assigned to Karus Therapeutics on December, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+39 characters)
Article
Patent abstract
A compound of formula I:
Edits on 11 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 4 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Alexander Richard Liam Cecil0
Franck Alexandre Silva0
Stephen Joseph Shuttleworth0
Edits on 26 Jul, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 22 Apr, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 25 Mar, 2023
Golden AI
Infobox
Patent Citations
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
105135300
Date of Patent
December 24, 2019
0Patent Application Number
159614040
Date Filed
April 24, 2018
0Patent Citations
Patent Citations Received
Patent Primary Examiner
Golden AI
Infobox
Edits on 8 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 31 Jan, 2022
Golden AI
Edits made to:
Infobox (+11 properties)
US Patent 10513530 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10513530
Date of patent
December 24, 2019
Patent application number
15961404
Date Filed
April 24, 2018
Patent citations
Patent primary examiner
Find more entities like US Patent 10513530 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
